Aldeyra Therapeutics, Inc.ALDX
Market cap
$300.08M
P/E ratio
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Stock-based compensation | 2 | 2 | 3 | 3 | 4 | 8 | 7 | 7 | 8 | 6 | 8 |
| Cash from operations | -4,775,994 | -9,311,753 | -15,147,512 | -19,222,862 | -29,857,131 | -44,984,226 | -37,493,455 | -42,555,907 | -56,637,187 | -30,326,128 | -43,208,747 |
| Capital expenditures | -14,062 | -86,119 | -11,810 | -24,759 | -262,966 | -9,529 | - | -7,806 | -16,317 | - | - |
| Cash from investing | -14,062 | -13,036,256 | -225,234 | -10,197,842 | -23,335,576 | 18 | 29 | -7,806 | -29,954,530 | 30 | -44,915,755 |
| Proceeds from issuance of term debt, net | - | - | - | - | - | 14 | - | - | - | - | - |
| Cash from financing | 10 | 28 | 13 | 37 | 81 | 24 | 42 | 194 | 1 | -1,270,220 | -171,422 |
| Free cash flow | - | - | - |